Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 7842 pages

Showing 7301 - 7350


prostate cancer

Minority of Older Patients With Low-Risk Prostate Cancer Managed by Observation

Most older men with low-risk prostate cancer receive upfront treatment, despite absence of clear survival benefit and potential for morbidity. In a retrospective cohort study reported in JAMA Internal Medicine, Hoffman et al found that use of observation as management in this setting varied widely...

supportive care
survivorship

No Clinical Outcome Benefit With Aerobic Training Program in Cancer Patients With Heart Failure

In a retrospective analysis in the HF-ACTION trial reported in the Journal of Clinical Oncology, Jones et al found that a program of aerobic training did not reduce the rate of all-cause mortality or hospitalization in cancer patients with heart failure. Some evidence suggested that patients who...

multiple myeloma

Lenalidomide, Bortezomib, and Dexamethasone Induction and Consolidation Effective in Multiple Myeloma in French Phase II Trial

In a phase II Intergroupe Francophone du Myélome (IFM) trial reported in the Journal of Clinical Oncology by Roussel et al, induction and consolidation treatment with RVD (lenalidomide [Revlimid], bortezomib [Velcade], and dexamethasone) followed by lenalidomide maintenance was associated...

skin cancer

Lymphovascular Invasion and Regression Identified as Independent Prognostic Factors in Thin Melanoma

In a European study reported in the Journal of Clinical Oncology, Maurichi et al identified lymphovascular invasion and regression as important prognostic factors in thin melanoma. They developed a nomogram including age, mitotic rate, ulceration, lymphovascular invasion, regression, and sentinel...

head and neck cancer

Meta-Analysis Indicates Better Outcomes With Charged-Particle Therapy vs Photon Therapy in Nasal Cavity and Paranasal Sinus Malignancies

Nasal cavity and paranasal sinus tumors are rare and comprise multiple histologic types, making comparative therapeutic trials difficult. In a systematic review and meta-analysis reported in The Lancet Oncology, Patel et al found that that charged-particle therapy appeared to be associated with...

colorectal cancer

Poorer Progression-Free Survival and Overall Survival Seen in Youngest and Oldest Patients With Metastatic Colorectal Cancer

Lieu et al recently analyzed the effect of age on outcome in patients with metastatic colorectal cancer using the ARCAD (Aide et Recherche en Cancérologie Digestive) database. The findings, reported in the Journal of Clinical Oncology, indicate a U-shaped risk of death and death or...

colorectal cancer

Effects of Aspirin, Hormone Replacement Therapy, Smoking, and BMI on Age- and Cancer-Associated DNA Methylation in the Colon in Women

In a study reported in the Journal of the National Cancer Institute, Noreen et al found that aspirin and hormone-replacement therapy reduced age-related gene promoter DNA methylation, and smoking and high body mass index (BMI) increased methylation in the colonic mucosa in women. Similar...

breast cancer

Cutaneous Embolization of Doxorubicin Drug-Eluting Beads in Patient With Liver Metastases From Breast Cancer

In a case report in JAMA Dermatology, Grieshaber et al describe finding cutaneous embolization of doxorubicin-eluting microspheres following transarterial chemoembolization in a woman with unresectable liver metastasis from breast cancer. Presentation The patient presented with painful pruritic...

head and neck cancer

Adjuvant Chemoradiation With Docetaxel Plus Cetuximab Shows Promise in High-Risk Squamous Cell Carcinoma of the Head and Neck

In the phase II Radiation Therapy Oncology Group (RTOG)-0234 trial reported in the Journal of Clinical Oncology, Harari et al found that adjuvant chemoradiation with docetaxel or cisplatin plus cetuximab (Erbitux) in patients with squamous cell carcinoma of the head and neck and high-risk...

prostate cancer

New Androgen Receptor Inhibitor Shows Activity in Metastatic Castration-Resistant Prostate Cancer

ODM-201 is a novel androgen receptor inhibitor—structurally distinct from enzalutamide (Xtandi)—that acts via high-affinity binding to the androgen receptor and inhibition of receptor nuclear translocation. In the phase I/II ARADES trial reported in The Lancet Oncology, Fizazi et al...

solid tumors
prostate cancer

Vasectomy Associated With Modestly Increased Risk of High-Grade and Lethal Prostate Cancer

An analysis of data from the Health Professionals Follow-Up Study reported by Siddiqui et al in the Journal of Clinical Oncology indicates that vasectomy is associated with a modestly but significantly increased risk of high-grade and lethal prostate cancer. The study involved data from 49,405...

lung cancer

Adding Ziv-Aflibercept to Topotecan Improves Progression-Free Survival but Increases Toxicity in Platinum-Treated Small Cell Lung Cancer

The phase II Southwest Oncology Group (SWOG) S0802 trial reported in the Journal of Clinical Oncology by Allen et al showed that adding ziv-aflibercept (Zaltrap) to topotecan improved 3-month progression-free survival, but increased toxicity and had no effect on overall survival, in patients...

skin cancer
skin cancer
issues in oncology

Total-Body Photography and Sequential Digital Dermoscopy Assist in Early Diagnosis of Primary Melanoma in High-Risk Individuals

In a study intended to help define optimal screening in individuals at high risk of melanoma, Moloney et al evaluated use of full-body examinations every 6 months along with dermoscopy and total-body photography for all patients and sequential digital dermoscopy imaging as indicated. The study,...

issues in oncology

Study Identifies Irinotecan Dosing Levels Based on UGT1A1 Genotype

Risk of severe irinotecan-associated neutropenia is related in part to presence of the UGT1A1*28 variant, which is linked to reduced elimination of the irinotecan active metabolite SN-38. In a study reported in the Journal of Clinical Oncology, Innocenti et al identified appropriate irinotecan...

supportive care

Long-Term Central Venous Catheter Use Associated With Three- to Sixfold Increased Risk of Infection in Older Patients With Cancer

In a retrospective SEER (Surveillance, Epidemiology, and End Results)/Medicare data analysis reported in the Journal of Clinical Oncology, Lipitz-Snyderman et al found that long-term central venous catheter use was associated with a three- to sixfold increase in risk of infection in older...

multiple myeloma

High-Dose Melphalan Plus Autologous Stem Cell Transplantation as Consolidation Shows Benefit in Relapsed Multiple Myeloma After Previous Transplant

In a UK phase III trial (NCRI Myeloma X Relapse [Intensive] Trial) reported in The Lancet Oncology, Cook et al found that high-dose melphalan plus salvage autologous stem cell transplantation significantly prolonged time to progression vs cyclophosphamide in patients with relapsed multiple myeloma...

sarcoma

Cyclophosphamide Noninferior to Ifosfamide as Part of Consolidation Treatment in Standard-Risk Ewing Sarcoma

In a European phase III noninferiority trial (Euro-EWING99-R1) reported in the Journal of Clinical Oncology, Le Deley et al found that cyclophosphamide was noninferior in event-free survival vs ifosfamide in combination with vincristine/dactinomycin as consolidation therapy in patients with...

issues in oncology

Patient Navigation Improves Time to Diagnosis Resolution and Treatment Initiation

In the Patient Navigation Research Program study reported in the Journal of the National Cancer Institute, Freund et al found that a patient navigation intervention improved diagnostic resolution and timely treatment initiation in a clinical population comprising predominantly racial/ethnic...

head and neck cancer
gastroesophageal cancer

French Phase III Trial Shows No Benefit of Neoadjuvant Chemoradiation in Stage I and II Esophageal Cancer

The effect of neoadjuvant chemoradiation therapy in early-stage esophageal cancer is not clear. In the phase III FFCD 9901 trial reported in the Journal of Clinical Oncology, Mariette et al found that neoadjuvant chemoradiation including fluorouracil (5-FU) and cisplatin did not improve R0...

colorectal cancer
issues in oncology

Study Identifies Patient and Tumor Characteristics Associated With BRAF and KRAS Mutations in Colon Cancer

In a study in the population of the North Central Cancer Treatment Group (NCCTG)/Alliance N0147 adjuvant trial reported in the Journal of the National Cancer Institute, Gonsalves et al identified patient and tumor characteristics that are associated with KRAS and BRAF V600E mutations in colon...

breast cancer

Frailty Predicts Noninitiation but Not Discontinuation of Adjuvant Hormonal Therapy in Older Women With Breast Cancer

In a study reported in the Journal of Clinical Oncology, Sheppard et al found that frailty was a significant predictor of not starting adjuvant hormonal therapy in breast cancer patients aged ≥ 65 years, but was not predictive of discontinuation of treatment. Study Details The study was...

hepatobiliary cancer

No Survival Benefit With Everolimus After Failure of Sorafenib in Advanced Hepatocellular Carcinoma

The multikinase inhibitor sorafenib (Nexavar) is the only effective systemic treatment available in advanced hepatocellular carcinoma. In the phase III EVOLVE-1 trial reported in JAMA, Zhu et al found no survival benefit from treatment with the mTOR inhibitor everolimus (Afinitor) after sorafenib...

breast cancer

Adjuvant Paclitaxel Not Equivalent to Doxorubicin/Cyclophosphamide in Breast Cancer With 0 to 3 Positive Axillary Nodes

In the phase III Cancer and Leukemia Group B (CALGB) 40101/Alliance trial reported in the Journal of Clinical Oncology, Shulman et al found that noninferiority of adjuvant single-agent paclitaxel was not established vs doxorubicin/cyclophosphamide for relapse-free survival in women with operable...

gynecologic cancers
issues in oncology

ABCA Transporter Gene Expression Is Associated With Poor Outcome in Epithelial Ovarian Cancer

In a study reported in the Journal of the National Cancer Institute, Hedditch et al found that expression of ATP-binding cassette (ABC) transporter genes of the A subfamily (ABCA) had a significant impact on outcome in epithelial ovarian cancer. High ABCA1, Low ABCA5 Expression Analysis of gene...

pancreatic cancer

Adding Oxaliplatin to Leucovorin/Fluorouracil Increases Survival in Second-Line Treatment of Gemcitabine-Refractory Pancreatic Cancer

In the German phase III CONKO-003 trial reported in the Journal of Clinical Oncology, Oettle et al found that second-line oxaliplatin, leucovorin, and fluorouracil (5-FU) significantly increased overall survival and time to progression vs leucovorin/5-FU in patients with advanced pancreatic cancer...

solid tumors

No Survival Benefit of Video-Assisted Thoracoscopic Partial Pleurectomy vs Talc Pleurodesis in Malignant Pleural Mesothelioma

In light of nonrandomized studies suggesting benefit of video-assisted thoracoscopic partial pleurectomy (VAT-PP) in symptom control and survival, Rintoul et al performed a randomized trial (MesoVATS) of VAT-PP vs talc pleurodesis in malignant pleural mesothelioma. As reported in The Lancet, this...

No Increased Risk for Cancer in Patients Receiving Tumor Necrosis Factor–Alpha Antagonists for Inflammatory Bowel Disease

Some data indicate an increased risk for cancer in patients receiving tumor necrosis factor (TNF)-alpha antagonists (eg, infliximab [Remicade], adalimumab [Humira], certolizumab pegol [Cimzia]) for rheumatoid arthritis. Studies with follow-up of ≤ 1 year have not found increased risk in patients ...

lung cancer

Propensity-Matched Analysis Shows Similar Outcomes for Segmentectomy vs Lobectomy in Stage I NSCLC

Recent retrospective, single-institution analyses have suggested that anatomic segmentectomy results in freedom from recurrence and survival rates similar to those achieved by lobectomy in lung cancer. In a large propensity-matched analysis reported in the Journal of Clinical Oncology, Landreneau...

breast cancer
gynecologic cancers
issues in oncology

Study Identifies Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

In a systematic review and meta-analysis reported in the Journal of the National Cancer Institute, Friebel et al attempted to identify factors that appear to modulate risk of breast and ovarian cancer in women who have inherited BRCA1 or BRCA2 mutations. Although the ability to perform...

lung cancer

No Improvement in Local Recurrence With Brachytherapy After Sublobar Resection in Patients With High-Risk Stage I NSCLC

In the phase III American College of Surgeons Oncology Group (ACOSOG) Z4032/Alliance trial reported in the Journal of Clinical Oncology, Fernando et al found that adjuvant brachytherapy did not improve risk for local recurrence after sublobar resection in patients with high-risk stage I operable...

breast cancer
issues in oncology

Abbreviated Screening MRI Protocol Is Highly Accurate in Breast Cancer Detection in Women at Increased Risk

As reported in the Journal of Clinical Oncology, Kuhl et al assessed whether an abbreviated breast magnetic resonance imaging (MRI) protocol, consisting of one pre- and one postcontrast acquisition and derived images—first postcontrast–subtracted (FAST) and maximum-intensity...

breast cancer
issues in oncology

Study Shows Annual MRI Plus Mammography May Be Effective Screening Program for Women at High Risk for Breast Cancer

The Ontario Breast Screening Program expanded in July 2011 to include screening of high-risk women aged 30 to 69 years with annual magnetic resonance imaging (MRI) and digital mammography. As reported by Chiarelli et al in Journal of Clinical Oncology, a study of the initial screen in the program...

colorectal cancer
issues in oncology
issues in oncology

Multifaceted Intervention Improves Adherence to Annual Colorectal Cancer Screening in Primarily Latino Community Health Centers

Colorectal cancer screening rates are low among Latinos and people living in poverty. In a study reported in JAMA Internal Medicine, Baker et al found that a multifaceted intervention more than doubled adherence to screening with fecal occult blood testing in a largely Latino and uninsured...

colorectal cancer

5-Year Results of the European EXPERT-C Trial Show Benefit of Cetuximab in TP53 Wild-Type Rectal Cancer Subgroup

In an updated analysis of the European phase II EXPERT-C trial reported in the Journal of the National Cancer Institute, Sclafani et al found that adding cetuximab (Erbitux) to neoadjuvant capecitabine plus oxaliplatin (CAPOX) followed by chemoradiotherapy, surgery, and adjuvant CAPOX produced no...

solid tumors
gastroesophageal cancer

Adding Rilotumumab to First-Line Chemotherapy May Benefit Patients With Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Hepatocyte growth factor (HGF) and its receptor MET have been found to promote the proliferation, migration, and survival of tumor cells and to play a role in gastric cancer. In a phase II study reported in The Lancet Oncology, Iveson et al found evidence of benefit from adding the anti-HGF...

colorectal cancer

Postdiagnosis Calcium and Milk Intake May Be Associated With Improved Overall Survival in Colorectal Cancer Patients

Higher intakes of calcium, vitamin D, and dairy product are associated with lower risk of colorectal cancer, but the effect of such intake on survival in colorectal cancer is unclear. In a study reported in the Journal of Clinical Oncology, Yang et al found that higher postdiagnosis intake of...

leukemia
survivorship

Excess Risk of Chronic Late Effects of Treatment in Children With Standard-Risk ALL

Given the changes in treatment of children with acute lymphoblastic leukemia (ALL), the risk of late effects in those treated with current protocols may be different from that in children treated decades ago. In a study of survivors of childhood standard-risk ALL reported in The Lancet Oncology,...

breast cancer

Telephone-Based Intervention Produces Weight Loss in Postmenopausal Women With Breast Cancer Receiving Letrozole

Obesity is associated with poorer outcome in women with operable breast cancer. In the LISA study reported in the Journal of Clinical Oncology, Goodwin et al found that a 24-month telephone-based intervention was effective in reducing body weight in postmenopausal breast cancer patients receiving...

skin cancer

Phase II Trial Shows Improved Progression-Free Survival but Greater Toxicity With Selumetinib vs Chemotherapy in Metastatic Uveal Melanoma

Oncogenic mutations in GNAQ and GNA11, resulting in MAPK pathway activation, are observed in > 80% of uveal melanomas. In a phase II trial reported in JAMA, Carvajal et al found that treatment with the MEK1/MEK2 inhibitor selumetinib significantly prolonged progression-free survival vs...

breast cancer
health-care policy

Immediate Breast Reconstruction After Mastectomy More Likely Among Canadian Women With Higher Income Who Are Treated at Teaching Hospitals

In a study reported in the Journal of Clinical Oncology, Zhong et al assessed factors associated with use of immediate breast reconstruction after treatment or prophylaxis for breast cancer among women in the Canadian universal health-care system. Immediate breast reconstruction was more likely in...

pancreatic cancer

No Benefit of Adding Telomerase Peptide Vaccine to Chemotherapy in Patients With Advanced Pancreatic Cancer

In a UK phase III TeloVac trial reported in The Lancet Oncology, Middleton et al found that the sequential or concurrent addition of the telomerase peptide vaccine GV1001 to gemcitabine/capecitabine did not improve survival in patients with locally advanced or metastatic pancreatic cancer. GV1001...

health-care policy

Uninsured Young Adults Have Poorer Cancer-Specific Outcomes

The Patient Protection and Affordable Care Act is likely to improve insurance coverage for young adults. In a study reported in the Journal of Clinical Oncology, Aizer et al examined the association between insurance status and cancer outcomes among young adults, finding that the uninsured...

head and neck cancer

HPV-Positive Disease Predicts Longer Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma

Patients with human papillomavirus (HPV)-positive oropharyngeal cancer have reduced risk of progression compared with those with HPV-negative disease, but the effect of HPV status on overall survival after progression has not been clear. In a study reported in the Journal of Clinical Oncology,...

colorectal cancer

No Disease-Free Survival Benefit of Adding Cetuximab to FOLFOX4 in KRAS Exon 2 Wild-Type Resected Stage III Colon Cancer

In an interim analysis of the European phase III PETACC-8 trial reported in The Lancet Oncology, Taieb et al found no disease-free survival or overall survival benefit with the addition of cetuximab (Erbitux) to standard adjuvant FOLFOX4 (oxaliplatin, fluorouracil, leucovorin) therapy in patients...

issues in oncology

High Neutrophil-to-Lymphocyte Ratio Is Associated With Poorer Survival in Solid Tumors Overall and in Individual Cancer Types

In a systematic review and meta-analysis reported in Journal of the National Cancer Institute, Templeton et al found that high neutrophil-to-lymphocyte ratio, a marker of inflammation, is associated with significantly poorer overall survival in solid tumors overall and by individual category. High...

leukemia

Event-Free Survival Benefit, Greater Toxicity of Augmented Postremission Therapy for Children/Young Adults With High-Risk Acute Lymphoblastic Leukemia

In a UK phase III trial (UKALL 2003) reported in The Lancet Oncology, Vora et al found that augmented postremission therapy provided an event-free survival benefit at the cost of increased toxicity in children and young adults with clinical standard- or intermediate-risk but minimal residual...

solid tumors

Phase III Trial Indicates That S-1 Monotherapy Should Remain Standard Treatment of Locally Advanced Gastric Cancer in Japan

The oral fluoropyrimidine S-1 is standard treatment for locally advanced gastric cancer in Japan. In a Japanese phase III trial (SAMIT) in locally advanced disease reported in The Lancet Oncology, Tsuburaya et al found that sequential paclitaxel plus tegafur and uracil or S-1 did not improve...

gastroesophageal cancer

No Overall Survival Improvement but Some Palliative Benefit With Gefitinib vs Placebo in Esophageal Cancer Progressing After Chemotherapy

In what may be the first randomized trial of systemic therapy in this setting, Dutton and colleagues evaluated gefitinib (Iressa) vs placebo in patients with esophageal cancer progressing after chemotherapy. As reported in The Lancet Oncology, the COG trial showed no survival benefit with gefitinib ...

issues in oncology

Oncologist Communication Skills Training Program Effective for Both Oncologists and Patients

In a Japanese study reported in the Journal of Clinical Oncology, Fujimori et al found that an oncologist communication skills training program based on patient preferences in receiving bad news was of benefit to both oncologists and patients. Study Details In the study, 30 oncologists were...

breast cancer

Tumor Microenvironment of Metastasis Score Independently Predicts Distant Metastasis in Estrogen Receptor–Positive/HER2-Negative Breast Cancer

Tumor microenvironment of metastasis (TMEM) consists of direct contact between a macrophage, an endothelial cell, and a tumor cell. In a case-control study reported in the Journal of the National Cancer Institute, Rohan et al found that TMEM score was an independent predictor of distant metastasis...

Advertisement

Advertisement




Advertisement